{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:44:47Z","timestamp":1783464287434,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T00:00:00Z","timestamp":1474502400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001273","name":"CHILDREN with CANCER UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010089","name":"JGW Patterson Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010089","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00280-016-3153-0","type":"journal-article","created":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T19:05:24Z","timestamp":1474571124000},"page":"1093-1096","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients"],"prefix":"10.1007","volume":"78","author":[{"given":"Victoria J.","family":"Forster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik W.","family":"van Delft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan F.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Mair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Halsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,22]]},"reference":[{"issue":"3","key":"3153_CR1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","volume":"14","author":"A Vora","year":"2013","unstructured":"Vora A, Goulden N, Wade R et al (2013) Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 14(3):199\u2013209","journal-title":"Lancet Oncol"},{"issue":"9","key":"3153_CR2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1200\/JCO.2013.53.0808","volume":"32","author":"D Bhojwani","year":"2014","unstructured":"Bhojwani D, Sabin ND, Pei D et al (2014) Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 32(9):949\u2013959","journal-title":"J Clin Oncol"},{"issue":"27","key":"3153_CR3","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1200\/JCO.2012.46.7050","volume":"31","author":"I Schuitema","year":"2013","unstructured":"Schuitema I, Deprez S, Van Hecke W et al (2013) Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25\u00a0years after pediatric lymphoid malignancies. J Clin Oncol 31(27):3378\u20133388","journal-title":"J Clin Oncol"},{"issue":"1","key":"3153_CR4","first-page":"25","volume":"24","author":"E Plas Van der","year":"2015","unstructured":"Van der Plas E, Nieman BJ, Butcher DT, Hitzler JK, Weksberg R, Ito S, Schachar R (2015) Neurocognitive late effects of chemotheapy in survivors of acute lymphoblastic leukemia: focus on methotrexate. J Can Acad Child Adolesc Psychiatry 24(1):25\u201332 (Winter)","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"issue":"3","key":"3153_CR5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1468-1331.2006.01659.x","volume":"14","author":"S Raghavendra","year":"2007","unstructured":"Raghavendra S, Nair MD, Chemmanam T, Krishnamoorthy T, Radhakrishnan VV, Kuruvilla A (2007) Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate. Eur J Neurol 14(3):309\u2013314","journal-title":"Eur J Neurol"},{"issue":"1","key":"3153_CR6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12311-013-0528-1","volume":"13","author":"I Gonzazlez-Suarez","year":"2014","unstructured":"Gonzazlez-Suarez I, Aquilar-Amat MJ, Triqueros M, Borobia AM, Cruz A, Arpa J (2014) Leukoencephalopathy due to oral methotrexate. Cerebellum 13(1):178\u2013183","journal-title":"Cerebellum"},{"issue":"26","key":"3153_CR7","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1182\/blood-2013-01-480335","volume":"121","author":"S Radtke","year":"2013","unstructured":"Radtke S, Zolk O, Renner B et al (2013) Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity and outcome in childhood acute lymphoblastic leukemia. Blood 121(26):5145\u20135153","journal-title":"Blood"},{"issue":"4","key":"3153_CR8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/pbc.25850","volume":"63","author":"C Badke","year":"2015","unstructured":"Badke C, Fleming A, Iqbal A, Khilji O, Parhas S, Weinstein J, Morgan E, Hiiya N (2015) Rechallenging with intrathecal methotrexate after developing subacute neurotoxicity in children with hematologic malignancies. Pediatr Blood Cancer 63(4):723\u2013726","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"3153_CR9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/pbc.25270","volume":"62","author":"U Lobel","year":"2015","unstructured":"Lobel U, Trah J, Escherich G (2015) Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer 62(3):539\u2013541","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"3153_CR10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1172\/JCI118862","volume":"98","author":"ME Chamberlin","year":"1996","unstructured":"Chamberlin ME, Ubagai T, Mudd SH, Wilson WG, Leonard JV, Chou JY (1996) Demyelination of the brain is associated with methionine adenosyltransferase I\/III deficiency. J Clin Invest 98(4):1021\u20131027","journal-title":"J Clin Invest"},{"issue":"2","key":"3153_CR11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bbr.2011.08.006","volume":"225","author":"V Vijayanathan","year":"2011","unstructured":"Vijayanathan V, Gulinello M, Ali N, Cole PD (2011) Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist. Behav Brain Res 225(2):491\u2013497","journal-title":"Behav Brain Res"},{"issue":"4","key":"3153_CR12","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.1998.16.4.1505","volume":"16","author":"R Surtees","year":"1998","unstructured":"Surtees R, Clelland J, Hann I (1998) Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. J Clin Oncol 16(4):1505\u20131511","journal-title":"J Clin Oncol"},{"issue":"1","key":"3153_CR13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","volume":"67","author":"K Suzuki","year":"2009","unstructured":"Suzuki K, Doki K, Homma M et al (2009) Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67(1):44\u201349","journal-title":"Br J Clin Pharmacol"},{"issue":"8098","key":"3153_CR14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(78)92341-3","volume":"2","author":"R Deacon","year":"1978","unstructured":"Deacon R, Lumb M, Perry J et al (1978) Selective inactivation of vitamin B12 in rats by nitrous oxide. Lancet 2(8098):1023\u20131024","journal-title":"Lancet"},{"issue":"Suppl 2","key":"3153_CR15","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/ajg.2009.45","volume":"104","author":"KE McColl","year":"2009","unstructured":"McColl KE (2009) Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 104(Suppl 2):S5\u2013S9","journal-title":"Am J Gastroenterol"},{"key":"3153_CR16","unstructured":"Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. http:\/\/www.medicinescomplete.com . Accessed 5 Feb 2016"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3153-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3153-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3153-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:30:43Z","timestamp":1498332643000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3153-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,22]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3153"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3153-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727455040.793530134","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,22]]}}}